• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Amivantamab, the first epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia.

作者信息

Cancel-Artau Karina J, Marrero-Pérez Angélica C, Michelén-Gómez Eduardo A, Sánchez-Flores Xavier

机构信息

Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.

University of Medicine and Health Sciences, Basseterre, Saint Kitts and Nevis.

出版信息

JAAD Case Rep. 2024 Jan 27;45:113-116. doi: 10.1016/j.jdcr.2024.01.014. eCollection 2024 Mar.

DOI:10.1016/j.jdcr.2024.01.014
PMID:38439765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10909656/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/87d2da6cba10/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/52892e97393e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/83b4d8c2686d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/87d2da6cba10/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/52892e97393e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/83b4d8c2686d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10909656/87d2da6cba10/gr3.jpg

相似文献

1
Amivantamab, the first epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia.阿米万他单抗是首个表皮生长因子受体和间充质上皮转化因子抑制剂，与阴茎及腹股沟溃疡和甲沟炎有关。
JAAD Case Rep. 2024 Jan 27;45:113-116. doi: 10.1016/j.jdcr.2024.01.014. eCollection 2024 Mar.
2
[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].[阿美替尼治疗EGFR/MET基因异常的非小细胞肺癌患者的疗效和安全性分析：单中心经验]
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):493-500. doi: 10.3779/j.issn.1009-3419.2022.102.26.
3
Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.阿米万他单抗：靶向非小细胞肺癌的新希望。
Anticancer Agents Med Chem. 2023;23(2):124-141. doi: 10.2174/1871520622666220523145609.
4
Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.针对非小细胞肺癌中的 EGFR 外显子 20 插入突变：Amivantamab 和 Mobocertinib。
Ann Pharmacother. 2023 Feb;57(2):198-206. doi: 10.1177/10600280221098398. Epub 2022 Jun 2.
5
Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.Amivantamab：一种针对非小细胞肺癌中 EGFR 外显子 20 插入的单克隆 EGFR-MET 双特异性抗体。
Drugs Today (Barc). 2022 Aug;58(8):389-398. doi: 10.1358/dot.2022.58.8.3432777.
6
Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.表皮毒性的管理下amivantamab（反 MET 和反 EGFR 双特异性抗体）在转移性非小细胞肺癌患者与表皮生长因子受体外显子 20 插入：走向一个积极的，多学科的方法。
Lung Cancer. 2022 Nov;173:116-123. doi: 10.1016/j.lungcan.2022.09.012. Epub 2022 Sep 27.
7
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.Amivantamab，一种表皮生长因子受体（EGFR）和间质上皮转化因子（MET）双特异性抗体，旨在实现多种作用机制和广泛的临床应用。
Clin Lung Cancer. 2023 Mar;24(2):89-97. doi: 10.1016/j.cllc.2022.11.004. Epub 2022 Nov 11.
8
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.发现双特异性抗体埃万妥单抗（JNJ-61186372），其靶向表皮生长因子受体（EGFR）和间质-上皮转化因子（MET）。
J Biol Chem. 2021 Jan-Jun;296:100641. doi: 10.1016/j.jbc.2021.100641. Epub 2021 Apr 8.
9
Amivantamab: First Approval.Amivantamab：首次批准。
Drugs. 2021 Jul;81(11):1349-1353. doi: 10.1007/s40265-021-01561-7.
10
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.阿美替尼治疗 EGFR 外显子 20 插入突变型非小细胞肺癌：CHRYSALIS Ⅰ期研究的初步结果。
J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.

本文引用的文献

1
Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction.
Indian J Dermatol Venereol Leprol. 2023;90(1):108-110. doi: 10.25259/IJDVL_717_2022.
2
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.FDA 批准概要：Amivantamab 用于治疗携带 EGFR 外显子 20 插入突变的非小细胞肺癌患者。
Clin Cancer Res. 2023 Sep 1;29(17):3262-3266. doi: 10.1158/1078-0432.CCR-22-3713.
3
MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis.用于治疗非小细胞肺癌的MET靶向疗法：一项系统评价与荟萃分析
Front Oncol. 2022 Oct 27;12:1013299. doi: 10.3389/fonc.2022.1013299. eCollection 2022.
4
Histological Features Associated With Human Mpox Virus Infection in 2022 Outbreak in a Nonendemic Country.2022年在一个非流行国家爆发的人类猴痘病毒感染相关的组织学特征
Clin Infect Dis. 2023 Mar 21;76(6):1132-1135. doi: 10.1093/cid/ciac856.
5
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.阿美替尼治疗 EGFR 外显子 20 插入突变型非小细胞肺癌：CHRYSALIS Ⅰ期研究的初步结果。
J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2.
6
Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung.吉非替尼诱发的转移性肺腺癌皮肤溃疡
Indian J Med Paediatr Oncol. 2014 Jan;35(1):109-10. doi: 10.4103/0971-5851.133736.
7
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.表皮生长因子受体抑制剂的皮肤副作用：“PRIDE”综合征
Indian J Dermatol. 2014 May;59(3):271-4. doi: 10.4103/0019-5154.131398.
8
Cutaneous side-effects of EGFR inhibitors and their management.表皮生长因子受体抑制剂的皮肤副作用及其处理
Skin Therapy Lett. 2011 Jan;16(1):1-3.
9
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.表皮生长因子受体抑制剂ZD1839在癌症患者皮肤中的药效学研究：受体抑制的组织病理学和分子学后果
J Clin Oncol. 2002 Jan 1;20(1):110-24. doi: 10.1200/JCO.2002.20.1.110.
10
EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation.表皮生长因子受体酪氨酸激酶抑制可诱导角质形成细胞生长停滞和终末分化。
J Invest Dermatol. 1997 Dec;109(6):751-6. doi: 10.1111/1523-1747.ep12340759.